Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study

Background: Bevacizumab was demonstrated to have efficacy in patients with NSCLC. However, application of different doses of bevacizumab in different clinical trials was overlooked. This study aims to investigate the effects and safety of different doses of bevacizumab in the treatment.Methods: From...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chun-Hua Zhou, Feng Yang, Wen-Juan Jiang, Yong-Chang Zhang, Hai-Yan Yang, Liang Zeng, Li Liu, Yi Xiong, Fan-Xu Zeng, Zhan Wang, Nong Yang
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	bevacizumab chemotherapy different dose efficacy and safety NSCLC Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/7acdcf1b87e249ddb0fe46e0a95b3d71
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7acdcf1b87e249ddb0fe46e0a95b3d71
record_format	dspace
spelling	oai:doaj.org-article:7acdcf1b87e249ddb0fe46e0a95b3d712021-11-17T06:40:16ZEfficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study1663-981210.3389/fphar.2021.727102https://doaj.org/article/7acdcf1b87e249ddb0fe46e0a95b3d712021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.727102/fullhttps://doaj.org/toc/1663-9812Background: Bevacizumab was demonstrated to have efficacy in patients with NSCLC. However, application of different doses of bevacizumab in different clinical trials was overlooked. This study aims to investigate the effects and safety of different doses of bevacizumab in the treatment.Methods: From January 2016 to March 2020, 79 patients with NSCLC received first-line combination treatment with chemotherapy (pemetrexed + platinum) and bevacizumab for four cycles; patients without progression after four cycles were randomly assigned to maintenance therapy with bevacizumab combined with pemetrexed, of which 57 patients received bevacizumab at a dose of 7.5 mg/kg and 22 patients at a dose of 15 mg/kg. The primary endpoint was progression-free survival, and secondary endpoints were overall response rate, disease control rate, and adverse events.Results: There was no significant difference between two groups in effectiveness; Median PFS in 7.5 mg/kg group and in 15 mg/kg group were 8.0 and 8.7 months, respectively (p = 0.663), reaching the primary endpoint. The ORR and DCR in the bevacizumab 7.5 and 15 mg/kg group were 45.46 and 86.0% vs. 50 and 90.9% showing no statistical significance (p = 0.804 and 0.717). Most of side effects were tolerable. The incidences of overall toxicities were higher in 15 mg/kg group (p = 0.001). No new safety signals were observed.Conclusion: We did not detect significant difference of efficacy and safety between 7.5 mg/kg group and 15 mg/kg group for bevacizumab administration, the cost-effectiveness of the 7.5 mg/kg group was significantly better than that of the 15 mg/kg group.Chun-Hua ZhouFeng YangWen-Juan JiangYong-Chang ZhangHai-Yan YangLiang ZengLi LiuYi XiongFan-Xu ZengZhan WangNong YangFrontiers Media S.A.articlebevacizumabchemotherapydifferent doseefficacy and safetyNSCLCTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	bevacizumab chemotherapy different dose efficacy and safety NSCLC Therapeutics. Pharmacology RM1-950
spellingShingle	bevacizumab chemotherapy different dose efficacy and safety NSCLC Therapeutics. Pharmacology RM1-950 Chun-Hua Zhou Feng Yang Wen-Juan Jiang Yong-Chang Zhang Hai-Yan Yang Liang Zeng Li Liu Yi Xiong Fan-Xu Zeng Zhan Wang Nong Yang Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study
description	Background: Bevacizumab was demonstrated to have efficacy in patients with NSCLC. However, application of different doses of bevacizumab in different clinical trials was overlooked. This study aims to investigate the effects and safety of different doses of bevacizumab in the treatment.Methods: From January 2016 to March 2020, 79 patients with NSCLC received first-line combination treatment with chemotherapy (pemetrexed + platinum) and bevacizumab for four cycles; patients without progression after four cycles were randomly assigned to maintenance therapy with bevacizumab combined with pemetrexed, of which 57 patients received bevacizumab at a dose of 7.5 mg/kg and 22 patients at a dose of 15 mg/kg. The primary endpoint was progression-free survival, and secondary endpoints were overall response rate, disease control rate, and adverse events.Results: There was no significant difference between two groups in effectiveness; Median PFS in 7.5 mg/kg group and in 15 mg/kg group were 8.0 and 8.7 months, respectively (p = 0.663), reaching the primary endpoint. The ORR and DCR in the bevacizumab 7.5 and 15 mg/kg group were 45.46 and 86.0% vs. 50 and 90.9% showing no statistical significance (p = 0.804 and 0.717). Most of side effects were tolerable. The incidences of overall toxicities were higher in 15 mg/kg group (p = 0.001). No new safety signals were observed.Conclusion: We did not detect significant difference of efficacy and safety between 7.5 mg/kg group and 15 mg/kg group for bevacizumab administration, the cost-effectiveness of the 7.5 mg/kg group was significantly better than that of the 15 mg/kg group.
format	article
author	Chun-Hua Zhou Feng Yang Wen-Juan Jiang Yong-Chang Zhang Hai-Yan Yang Liang Zeng Li Liu Yi Xiong Fan-Xu Zeng Zhan Wang Nong Yang
author_facet	Chun-Hua Zhou Feng Yang Wen-Juan Jiang Yong-Chang Zhang Hai-Yan Yang Liang Zeng Li Liu Yi Xiong Fan-Xu Zeng Zhan Wang Nong Yang
author_sort	Chun-Hua Zhou
title	Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study
title_short	Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study
title_full	Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study
title_fullStr	Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study
title_full_unstemmed	Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study
title_sort	efficacy and safety of different doses of bevacizumab combined with pemetrexed and platinum in first-line treatment of advanced nsclc: a retrospective-real world study
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/7acdcf1b87e249ddb0fe46e0a95b3d71
work_keys_str_mv	AT chunhuazhou efficacyandsafetyofdifferentdosesofbevacizumabcombinedwithpemetrexedandplatinuminfirstlinetreatmentofadvancednsclcaretrospectiverealworldstudy AT fengyang efficacyandsafetyofdifferentdosesofbevacizumabcombinedwithpemetrexedandplatinuminfirstlinetreatmentofadvancednsclcaretrospectiverealworldstudy AT wenjuanjiang efficacyandsafetyofdifferentdosesofbevacizumabcombinedwithpemetrexedandplatinuminfirstlinetreatmentofadvancednsclcaretrospectiverealworldstudy AT yongchangzhang efficacyandsafetyofdifferentdosesofbevacizumabcombinedwithpemetrexedandplatinuminfirstlinetreatmentofadvancednsclcaretrospectiverealworldstudy AT haiyanyang efficacyandsafetyofdifferentdosesofbevacizumabcombinedwithpemetrexedandplatinuminfirstlinetreatmentofadvancednsclcaretrospectiverealworldstudy AT liangzeng efficacyandsafetyofdifferentdosesofbevacizumabcombinedwithpemetrexedandplatinuminfirstlinetreatmentofadvancednsclcaretrospectiverealworldstudy AT liliu efficacyandsafetyofdifferentdosesofbevacizumabcombinedwithpemetrexedandplatinuminfirstlinetreatmentofadvancednsclcaretrospectiverealworldstudy AT yixiong efficacyandsafetyofdifferentdosesofbevacizumabcombinedwithpemetrexedandplatinuminfirstlinetreatmentofadvancednsclcaretrospectiverealworldstudy AT fanxuzeng efficacyandsafetyofdifferentdosesofbevacizumabcombinedwithpemetrexedandplatinuminfirstlinetreatmentofadvancednsclcaretrospectiverealworldstudy AT zhanwang efficacyandsafetyofdifferentdosesofbevacizumabcombinedwithpemetrexedandplatinuminfirstlinetreatmentofadvancednsclcaretrospectiverealworldstudy AT nongyang efficacyandsafetyofdifferentdosesofbevacizumabcombinedwithpemetrexedandplatinuminfirstlinetreatmentofadvancednsclcaretrospectiverealworldstudy
_version_	1718425867761221632

Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study

Ejemplares similares